Clinical Trials on Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma in Canada
Total 4 results
-
Forma Therapeutics, Inc.RecruitingVery Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-RUnited States, France, Canada, Germany
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaActive, not recruitingLow or Intermediate Risk Prostate CancerCanada
-
FibroGenAstraZeneca; Astellas Pharma IncTerminatedPrimary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
-
Monte Rosa Therapeutics, IncRecruitingNSCLC | Prostate Cancer | SCLC | DLBCL | High Grade Neuroendocrine Cancer | L-MYC and N-MYC Amplified Solid Tumors | NSCLC With High or Low L-MYC or N-MYC Expression | HR-positive, HER2-negative Breast CancerUnited States, Canada